Compare Sysmex Corp. with Similar Stocks
Dashboard
1
Weak Long Term Fundamental Strength with a 7.13% CAGR growth in Operating Profits over the last 5 years
2
Poor long term growth as Operating profit has grown by an annual rate 7.13% of over the last 5 years
3
Flat results in Jun 26
4
With ROE of 9.32%, it has a expensive valuation with a 1.78 Price to Book Value
5
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
JPY 975,065 Million (Large Cap)
19.00
NA
0.00%
-0.09
9.29%
1.93
Revenue and Profits:
Net Sales:
130,674 Million
(Quarterly Results - Jun 2026)
Net Profit:
8,616 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
33.35%
0%
33.35%
6 Months
32.96%
0%
32.96%
1 Year
-2.64%
0%
-2.64%
2 Years
-33.33%
0%
-33.33%
3 Years
-75.73%
0%
-75.73%
4 Years
-77.09%
0%
-77.09%
5 Years
-87.55%
0%
-87.55%
Sysmex Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
11.21%
EBIT Growth (5y)
7.13%
EBIT to Interest (avg)
39.04
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.10
Sales to Capital Employed (avg)
0.98
Tax Ratio
27.13%
Dividend Payout Ratio
66.79%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
20.40%
ROE (avg)
11.89%
Valuation key factors
Factor
Value
P/E Ratio
19
Industry P/E
Price to Book Value
1.78
EV to EBIT
12.15
EV to EBITDA
7.40
EV to Capital Employed
1.83
EV to Sales
1.70
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
15.09%
ROE (Latest)
9.32%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
Bullish
Shareholding Snapshot : Jun 2026
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 2 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
130,674.00
105,731.00
23.59%
Operating Profit (PBDIT) excl Other Income
28,514.00
20,523.00
38.94%
Interest
1,272.00
909.00
39.93%
Exceptional Items
0.00
0.00
Consolidate Net Profit
8,616.00
4,476.00
92.49%
Operating Profit Margin (Excl OI)
126.20%
92.30%
3.39%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 23.59% vs -5.55% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 92.49% vs -59.25% in Jun 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
500,006.00
508,643.00
-1.70%
Operating Profit (PBDIT) excl Other Income
108,606.00
128,708.00
-15.62%
Interest
3,800.00
2,995.00
26.88%
Exceptional Items
-12,115.00
-3,731.00
-224.71%
Consolidate Net Profit
35,374.00
53,576.00
-33.97%
Operating Profit Margin (Excl OI)
124.30%
176.30%
-5.20%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is -1.70% vs 10.21% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is -33.97% vs 7.64% in Mar 2025
About Sysmex Corp. 
Sysmex Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






